“`html
GRI Bio (NASDAQ: GRI), a La Jolla-based biotechnology firm targeting inflammatory, fibrotic, and autoimmune diseases through Natural Killer T cell modulation, is set to take the virtual stage at A.G.P.’s Annual Healthcare Showcase. The company’s chief architect, Dr. Marc Hertz, will participate in a candid fireside discussion on May 21, 2025, at 2:40 PM ET, offering insights into its novel immunotherapy strategies. Investors can tune in live via the events page at gribio.com.
05/16/2025 – 09:15 AM
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET
In the high-stakes arena of immune modulation, GRI Bio is shifting gears. The San Diego-based startup announced today that its CEO, Dr. Marc Hertz, will present groundbreaking research from the company’s iNKT cell inhibitor pipeline during A.G.P.’s digital healthcare expo. While the industry struggles with conventional T-cell therapies, GRI Bio is exploring what may be the overlooked “quarterbacks” of immune responses – NKT cells — betting this approach could reset treatment paradigms across multiple autoimmune conditions.
LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) — Unlike the typical cell therapy players competing in the CAR-T space, GRI Bio (NASDAQ: GRI) has carved out a niche targeting Type I invariant NKT cells. CEO Dr. Marc Hertz will share details of this unconventional strategy during the virtual fireside chat at A.G.P.’s Healthcare Showcase, scheduled for May 21, 2025, at 2:40 PM ET. Viewers can register for the event link.
Key Insights
How does GRI Bio’s NKT approach differ from conventional immunotherapy?M
Rather than targeting downstream immune mechanisms like typical biologics, GRI Bio intervenes earlier in the inflammatory cascade by modulating NKT cells — hybrid immune cells that bridge innate and adaptive immunity. This platform potentially addresses disease drivers rather than symptoms, with implications for trillions in pharmaceutical market value.
What pipeline milestones can investors expect?M
Beyond showcase presentations, Phase II data for GRI-0621 in idiopathic pulmonary fibrosis could arrive by late 2025, with lupus-related trials following close behind. The 500-compound library provides fertile ground for future asset development.
Why is A.G.P.’s Showcase significant for biotech investors?M
This virtual forum typically attracts over 500 investment professionals, providing startups like GRI Bio unprecedented visibility. Last year’s participants saw average stock jumps of 8% post-event, making it a crucial moment for market positioning.
View the full event details on GRI Bio’s investor portal.
About GRI Bio, Inc.
While the biotech field chases adaptive immunity, this firm is rewriting the playbook on innate immune targeting. Natural Killer T cells — the company’s sweet spot — orchestrate early inflammatory responses, creating unique therapeutic windows. With GRI-0621 in Phase II trials for idiopathic pulmonary fibrosis, the platform hints at blockbuster potential. Better yet? Their diverse NKT agonist subclass pipeline could become cornerstones for systemic lupus treatments. For immunotherapy investors, GRI Bio might represent the first shot across the bow of conventional autoimmune treatment thinking.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/339.html
